Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

The 2021 5th edition of the WHO Classification of Tumors of the Central Nervous System
reflects the discovery of genetic alterations underlying many central nervous system (CNS) …

BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n= 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …

Visual microscopic study of diseased tissue by pathologists has been the cornerstone for
cancer diagnosis and prognostication for more than a century. Recently, deep learning …

The fifth edition of the World Health Organization Classification of Tumours of the Central
Nervous System (WHO CNS5) published in 2021 builds on the 2016 edition and …

Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase
(TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive …

Establishing causal links between inherited polymorphisms and cancer risk is challenging.
Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold …

Simple Summary Pediatric brain tumors represent a formidable challenge in the field of
oncology. Pediatric brain tumors are sub-classified into several molecular sub-types, where …

Purpose Pediatric low-grade gliomas (pLGGs) are the most common CNS tumor of
childhood and comprise a heterogenous group of tumors. Children with progressive pLGG …

Abstract Purpose of Review Pediatric low-grade gliomas and glioneuronal tumors (pLGG)
account for approximately 30% of pediatric CNS neoplasms, encompassing a …